SRPT Today - Aug 10: CEO Change and Demand Issues

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

SRPT Today - Aug 10: CEO Change and Demand Issues

無料で聴く

ポッドキャストの詳細を見る

Hey, what’s up? It’s Joey here, your friendly neighborhood investor, breaking down the day for you. Today we're talking about Sarepta, or SRPT, and it was a bit of a red day. The stock dipped about 1.3%.

So, what went down? Well, it started off with some buzz after they named a new CEO, which gave the stock a little lift earlier in the day. But then, after-hours trading hit hard, and it dropped about 7% as people started freaking out over slumping demand for Elevidys, their gene therapy product. Yeah, that one stung. It’s like a rollercoaster—up and then straight down.

Now, why the drama? The new CEO announcement initially made folks think there could be fresh energy and direction for the company. But then, the reality check came when the after-hours news broke. Demand for Elevidys isn’t looking great, and that’s a big deal since it’s one of their main products. Investors seemed to lose confidence fast, hitting that sell button like it was a hot potato.

One thing to keep in mind is that the CEO still believes they can bounce back to growth despite the current hiccup. So, there’s that glimmer of hope for the future, but it's definitely a bumpy ride right now.

Wrapping it up, Sarepta had a rocky day, caught between a new leadership vibe and some not-so-great news on their product demand. Just remember, this is all about keeping you in the loop, not giving financial advice. Stay chill, and catch you next time!

まだレビューはありません